ARGX logo

argenx SE (ARGX)

$947.52

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ARGX

Market cap

$58.81B

EPS

19.57

P/E ratio

42.1

Price to sales

12.33

Dividend yield

--

Beta

0.486783

Price on ARGX

Previous close

$950.95

Today's open

$935.68

Day's range

$934.66 - $952.37

52 week range

$661.85 - $1,072.75

Profile about ARGX

CEO

Tim Van Hauwermeiren

Employees

1863

Headquarters

Amsterdam,

Exchange

Nasdaq Global Select

Shares outstanding

62062888

Issue type

American Depository Receipt

ARGX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ARGX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.

news source

The Motley Fool • Nov 9, 2026

news preview

argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. This acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion

news source

GlobeNewsWire • Nov 9, 2026

news preview

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 2026, 10:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR) Convergence 2026 on November 11, 2026, from 9:15-9:30 a.m. ET. Combined IMNM and DM population: Primary and key secondary endpoints met The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6).

news source

GlobeNewsWire • Nov 7, 2026

news preview

Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX

Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).

news source

Zacks Investment Research • Nov 4, 2026

news preview

argenx to Present at Upcoming Investor Conferences

November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.

news source

GlobeNewsWire • Nov 3, 2026

news preview

argenx: 3 Key Takeaways for Long-Term Investors

Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.

news source

The Motley Fool • Oct 23, 2026

news preview

Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans

Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.

news source

Investors Business Daily • Oct 22, 2026

news preview

What argenex (ARGX) Said on Its Q3 Earnings Call

argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.

news source

MarketBeat • Oct 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in argenx SE

Open an M1 investment account to buy and sell argenx SE commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ARGX on M1